NCT06381154 2026-01-30
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
9 trialsNCT02153229 2025-12-26
MPM-PDT
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT05020912 2025-11-26
Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT03945162 2025-11-24
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
TheralaseĀ® Technologies Inc.
Phase 2 Recruiting
NCT03033225 2025-07-30
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
Mayo Clinic
Phase 2 Completed
NCT04429308 2025-05-08
PDT vs Peels for Treatment of Actinic Keratoses
Northwestern University
Phase 2 Not yet recruiting
NCT05386056 2022-11-28
Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Unknown
NCT03090412 2022-06-02
Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT02068157 2017-10-11
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
Roswell Park Cancer Institute
Phase 2 Terminated